Hartong S C, Neelis K J, Visser T P, Wagemaker G
Institute of Hematology, Erasmus University Rotterdam, The Netherlands.
Exp Hematol. 2000 Jul;28(7):753-9. doi: 10.1016/s0301-472x(00)00171-5.
If administered in a sufficiently high dose to overcome receptor-mediated clearance and in a well-scheduled manner, thrombopoietin (TPO) prominently stimulates hematopoietic reconstitution following myelosuppressive treatment and potentiates the efficacy of both granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF). However, TPO alone is not effective after bone marrow transplantation. Based on results of GM-CSF and TPO treatment after myelosuppression that resulted in augmented thrombocyte, reticulocyte, and leukocyte regeneration, we evaluated TPO/GM-CSF treatment after lethal irradiation followed by autologous bone marrow transplantation.
Young adult Rhesus monkeys were subjected to 8-Gy total body irradiation (TBI) (x-rays) followed by transplantation of 10(7)/kg unfractionated bone marrow cells. TPO 5 microg/kg was administered intravenously at day 0 to obtain rapidly high levels. Animals then were treated with 5 microg/kg Rhesus TPO and 25 microg/kg GM-CSF given SC on days 1 to 14 after TBI.
The grafts shortened the profound pancytopenia induced by 8-Gy TBI from 5-6 weeks to 3 weeks. The combination of TPO and GM-CSF did not significantly influence the recovery patterns of thrombocytes (p = 0.39), reticulocytes (p = 0.08), white blood cells (p = 0.08), or bone marrow progenitors compared to TPO alone.
The present study demonstrates that, after high-dose TBI and transplantation of a limited number of unfractionated bone marrow cells, simultaneous administration of TPO and GM-CSF after TBI is ineffective in preventing pancytopenia. This result contrasts sharply with the prominent stimulation observed in a 5-Gy TBI myelosuppression model, despite a similar level of pancytopenia in the 8-Gy model of the present study. The discordant results of this growth factor combination in these two models may imply codependence of the hematopoietic response to TPO and/or GM-CSF on other factors or cytokines.
若以足够高的剂量给药以克服受体介导的清除作用,并以合理的给药方案进行给药,血小板生成素(TPO)在骨髓抑制治疗后能显著刺激造血重建,并增强粒细胞-巨噬细胞集落刺激因子(GM-CSF)和粒细胞集落刺激因子(G-CSF)的疗效。然而,单独使用TPO在骨髓移植后并无效果。基于骨髓抑制后GM-CSF和TPO治疗导致血小板、网织红细胞和白细胞再生增强的结果,我们评估了致死性照射后自体骨髓移植的TPO/GM-CSF治疗。
对成年恒河猴进行8 Gy全身照射(TBI)(X射线),随后移植10(7)/kg未分级的骨髓细胞。在第0天静脉注射5 μg/kg TPO以迅速达到较高水平。然后在TBI后的第1至14天,给动物皮下注射5 μg/kg恒河猴TPO和25 μg/kg GM-CSF。
移植缩短了8 Gy TBI诱导的严重全血细胞减少期,从5 - 6周缩短至3周。与单独使用TPO相比,TPO和GM-CSF联合使用对血小板(p = 0.39)、网织红细胞(p = 0.08)、白细胞(p = 0.08)或骨髓祖细胞的恢复模式没有显著影响。
本研究表明,在大剂量TBI和移植有限数量的未分级骨髓细胞后,TBI后同时给予TPO和GM-CSF对预防全血细胞减少无效。这一结果与在5 Gy TBI骨髓抑制模型中观察到的显著刺激形成鲜明对比,尽管本研究的8 Gy模型中全血细胞减少的程度相似。这两种模型中这种生长因子组合的不一致结果可能意味着造血对TPO和/或GM-CSF的反应对其他因素或细胞因子存在共同依赖性。